Company intelligence

Johnson & Johnson

Pharma

Is something wrong on this page?

Latest Pulse

  1. Isomorphic Labs Raises $5B Series C | 2.4x Its $2.1B May RoundIsomorphic Labs raised a $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining, to push its AI-designed drug candidates toward clinical trials; the company did not disclose its valuation.→
  2. Ollin Biosciences Agrees To $2.2B J&J Sale | Up To $3.33B With MilestonesJohnson & Johnson agreed to acquire Ollin Biosciences for $2.2B upfront plus up to about $1.125B in milestones, adding OLN324, a bispecific eye drug it describes as Phase 3, as Blackstone funds $750M of its development.→
  3. Delix Therapeutics Raises $100M Series C For Depression Drug TrialDelix Therapeutics raised an oversubscribed $100 million Series C, co-led by Johnson & Johnson Innovation and SV Health's Dementia Discovery Fund, to advance its depression drug zalsupindole into Phase II trials.→
  4. T-Therapeutics Raises $133M Series B For Cancer, Autoimmune TCRsT-Therapeutics raised $133 million in an oversubscribed Series B to advance two first-in-class TCR-based therapies for cancer and autoimmune disease toward early clinical trials.→
  5. TRexBio Closes $116.7M IPO, Lilly Eyes Bigger StakeTRexBio closed its IPO on Oct. 13, selling 8.33 million shares at $14 for about $116.7 million, with largest shareholder Eli Lilly signaling interest in raising its stake.→
  6. Freehand Raises $75M Series B, Tops $100M TotalFreehand raised a $75 million Series B led by Battery Ventures, bringing total funding to $100 million for its AI system that negotiates, adjudicates and settles complex procurement spend.→
  7. Freehand Raises $75M to Automate Supply ChainsFreehand raised a $75 million Series B to scale AI agents that manage Fortune 500 supply-chain spend, with customers including Meta, Unilever, Pfizer and Johnson & Johnson already live on the platform.→
  8. SonoThera Raises $125M for Ultrasound Gene TherapySonoThera closed an oversubscribed $125 million Series B led by Vida Ventures to push its ultrasound-delivered, nonviral genetic medicine platform toward its first clinical trial in Duchenne muscular dystrophy in 2027.→

Coverage Timeline

newest first
  1. Nov 16, 2026FUNDINGOllin Biosciences Agrees To $2.2B J&J Sale | Up To $3.33B With Milestones$2.2B Upfront Acquisition→

All Coverage

Value Add Research